Investigation of Efficacy of incobotulinumtoxinA (Xeomin) in Relieving Symptoms of Restless Leg Syndrome.
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to compare the safety and effectiveness of local
injections of botulinum toxin A (Xeomin®) to an inactive test substance (placebo) in a
medical condition called Restless Leg Syndrome. This study has a double blind cross over
design. Cross over means that you will have two sets of injections. The first set of
injections can be either Xeomin or placebo. The order of injection will be reversed at the
three month point following the first injection. Double blind means neither the investigators
nor you know which one of the two (Xeomin or placebo) you received.
Phase:
Phase 2
Details
Lead Sponsor:
Yale University
Collaborators:
Merz North America, Inc. Merz Pharmaceuticals, LLC
Treatments:
abobotulinumtoxinA Botulinum Toxins, Type A incobotulinumtoxinA onabotulinumtoxinA